Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 147

1.

The influence of glucocorticoid receptor single nucleotide polymorphisms on outcome after haematopoietic stem cell transplantation.

Norden J, Pearce KF, Irving JAE, Collin MP, Wang XN, Wolff D, Kolb HJ, Socie G, Kuzmina Z, Greinix H, Holler E, Rocha V, Gluckman E, Hromadnikova I, Dickinson AM.

Int J Immunogenet. 2018 Jul 25. doi: 10.1111/iji.12380. [Epub ahead of print]

PMID:
30043490
2.

Genome-wide association study identifies susceptibility loci for B-cell childhood acute lymphoblastic leukemia.

Vijayakrishnan J, Studd J, Broderick P, Kinnersley B, Holroyd A, Law PJ, Kumar R, Allan JM, Harrison CJ, Moorman AV, Vora A, Roman E, Rachakonda S, Kinsey SE, Sheridan E, Thompson PD, Irving JA, Koehler R, Hoffmann P, Nöthen MM, Heilmann-Heimbach S, Jöckel KH, Easton DF, Pharaoh PDP, Dunning AM, Peto J, Canzian F, Swerdlow A, Eeles RA, Kote-Jarai Z, Muir K, Pashayan N, Greaves M, Zimmerman M, Bartram CR, Schrappe M, Stanulla M, Hemminki K, Houlston RS; PRACTICAL Consortium.

Nat Commun. 2018 Apr 9;9(1):1340. doi: 10.1038/s41467-018-03178-z.

3.

Probing the folding pathway of a consensus serpin using single tryptophan mutants.

Yang L, Irving JA, Dai W, Aguilar MI, Bottomley SP.

Sci Rep. 2018 Feb 1;8(1):2121. doi: 10.1038/s41598-018-19567-9.

4.

Ovarian Microcystic Stromal Tumors Are Characterized by Alterations in the Beta-Catenin-APC Pathway and May be an Extracolonic Manifestation of Familial Adenomatous Polyposis.

McCluggage WG, Irving JA, Chong AS, Clarke BA, Young RH, Foulkes WD, Rivera B.

Am J Surg Pathol. 2018 Jan;42(1):137-139. doi: 10.1097/PAS.0000000000000981. No abstract available.

PMID:
29076875
5.

Electrophoresis- and FRET-Based Measures of Serpin Polymerization.

Faull SV, Brown AE, Haq I, Irving JA.

Methods Mol Biol. 2017;1639:235-248. doi: 10.1007/978-1-4939-7163-3_24.

PMID:
28752464
6.

The pathological Trento variant of alpha-1-antitrypsin (E75V) shows nonclassical behaviour during polymerization.

Miranda E, Ferrarotti I, Berardelli R, Laffranchi M, Cerea M, Gangemi F, Haq I, Ottaviani S, Lomas DA, Irving JA, Fra A.

FEBS J. 2017 Jul;284(13):2110-2126. doi: 10.1111/febs.14111. Epub 2017 Jun 8.

7.

Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia.

Frismantas V, Dobay MP, Rinaldi A, Tchinda J, Dunn SH, Kunz J, Richter-Pechanska P, Marovca B, Pail O, Jenni S, Diaz-Flores E, Chang BH, Brown TJ, Collins RH, Uhrig S, Balasubramanian GP, Bandapalli OR, Higi S, Eugster S, Voegeli P, Delorenzi M, Cario G, Loh ML, Schrappe M, Stanulla M, Kulozik AE, Muckenthaler MU, Saha V, Irving JA, Meisel R, Radimerski T, Von Stackelberg A, Eckert C, Tyner JW, Horvath P, Bornhauser BC, Bourquin JP.

Blood. 2017 Mar 16;129(11):e26-e37. doi: 10.1182/blood-2016-09-738070. Epub 2017 Jan 25.

8.

CREBBP knockdown enhances RAS/RAF/MEK/ERK signaling in Ras pathway mutated acute lymphoblastic leukemia but does not modulate chemotherapeutic response.

Dixon ZA, Nicholson L, Zeppetzauer M, Matheson E, Sinclair P, Harrison CJ, Irving JA.

Haematologica. 2017 Apr;102(4):736-745. doi: 10.3324/haematol.2016.145177. Epub 2016 Dec 15.

9.

A genome-wide association study identifies risk loci for childhood acute lymphoblastic leukemia at 10q26.13 and 12q23.1.

Vijayakrishnan J, Kumar R, Henrion MY, Moorman AV, Rachakonda PS, Hosen I, da Silva Filho MI, Holroyd A, Dobbins SE, Koehler R, Thomsen H, Irving JA, Allan JM, Lightfoot T, Roman E, Kinsey SE, Sheridan E, Thompson PD, Hoffmann P, Nöthen MM, Heilmann-Heimbach S, Jöckel KH, Greaves M, Harrison CJ, Bartram CR, Schrappe M, Stanulla M, Hemminki K, Houlston RS.

Leukemia. 2017 Mar;31(3):573-579. doi: 10.1038/leu.2016.271. Epub 2016 Oct 3.

10.

Smoothing a rugged protein folding landscape by sequence-based redesign.

Porebski BT, Keleher S, Hollins JJ, Nickson AA, Marijanovic EM, Borg NA, Costa MG, Pearce MA, Dai W, Zhu L, Irving JA, Hoke DE, Kass I, Whisstock JC, Bottomley SP, Webb GI, McGowan S, Buckle AM.

Sci Rep. 2016 Sep 26;6:33958. doi: 10.1038/srep33958.

11.

An antibody that prevents serpin polymerisation acts by inducing a novel allosteric behaviour.

Motamedi-Shad N, Jagger AM, Liedtke M, Faull SV, Nanda AS, Salvadori E, Wort JL, Kay CW, Heyer-Chauhan N, Miranda E, Perez J, Ordóñez A, Haq I, Irving JA, Lomas DA.

Biochem J. 2016 Oct 1;473(19):3269-90. doi: 10.1042/BCJ20160159. Epub 2016 Jul 12.

12.

Integration of genetic and clinical risk factors improves prognostication in relapsed childhood B-cell precursor acute lymphoblastic leukemia.

Irving JA, Enshaei A, Parker CA, Sutton R, Kuiper RP, Erhorn A, Minto L, Venn NC, Law T, Yu J, Schwab C, Davies R, Matheson E, Davies A, Sonneveld E, den Boer ML, Love SB, Harrison CJ, Hoogerbrugge PM, Revesz T, Saha V, Moorman AV.

Blood. 2016 Aug 18;128(7):911-22. doi: 10.1182/blood-2016-03-704973. Epub 2016 May 26.

13.

Xenograft-directed personalized therapy for a patient with post-transplant relapse of ALL.

Trahair TN, Lock RB, Sutton R, Sia KC, Evans K, Richmond J, Law T, Venn NC, Irving JA, Moore S, Nievergall E, Dang P, Heatley SL, White DL, Revesz T.

Bone Marrow Transplant. 2016 Sep;51(9):1279-82. doi: 10.1038/bmt.2016.122. Epub 2016 May 16. No abstract available.

PMID:
27183096
14.

The role of the RAS pathway in iAMP21-ALL.

Ryan SL, Matheson E, Grossmann V, Sinclair P, Bashton M, Schwab C, Towers W, Partington M, Elliott A, Minto L, Richardson S, Rahman T, Keavney B, Skinner R, Bown N, Haferlach T, Vandenberghe P, Haferlach C, Santibanez-Koref M, Moorman AV, Kohlmann A, Irving JA, Harrison CJ.

Leukemia. 2016 Sep;30(9):1824-31. doi: 10.1038/leu.2016.80. Epub 2016 Apr 22.

15.

The ability to cross the blood-cerebrospinal fluid barrier is a generic property of acute lymphoblastic leukemia blasts.

Williams MT, Yousafzai YM, Elder A, Rehe K, Bomken S, Frishman-Levy L, Tavor S, Sinclair P, Dormon K, Masic D, Perry T, Weston VJ, Kearns P, Blair H, Russell LJ, Heidenreich O, Irving JA, Izraeli S, Vormoor J, Graham GJ, Halsey C.

Blood. 2016 Apr 21;127(16):1998-2006. doi: 10.1182/blood-2015-08-665034. Epub 2016 Feb 11.

16.

Personalization of dexamethasone therapy in childhood acute lymphoblastic leukaemia.

Jackson RK, Irving JA, Veal GJ.

Br J Haematol. 2016 Apr;173(1):13-24. doi: 10.1111/bjh.13924. Epub 2016 Jan 5. Review.

PMID:
26729065
17.

Towards an understanding of the biology and targeted treatment of paediatric relapsed acute lymphoblastic leukaemia.

Irving JA.

Br J Haematol. 2016 Mar;172(5):655-66. doi: 10.1111/bjh.13852. Epub 2015 Nov 16. Review.

PMID:
26568036
18.

The 9p21.3 risk of childhood acute lymphoblastic leukaemia is explained by a rare high-impact variant in CDKN2A.

Vijayakrishnan J, Henrion M, Moorman AV, Fiege B, Kumar R, da Silva Filho MI, Holroyd A, Koehler R, Thomsen H, Irving JA, Allan JM, Lightfoot T, Roman E, Kinsey SE, Sheridan E, Thompson PD, Hoffmann P, Nöthen MM, Mühleisen TW, Eisele L, Bartram CR, Schrappe M, Greaves M, Hemminki K, Harrison CJ, Stanulla M, Houlston RS.

Sci Rep. 2015 Oct 14;5:15065. doi: 10.1038/srep15065.

19.

Interactions between N-linked glycosylation and polymerisation of neuroserpin within the endoplasmic reticulum.

Moriconi C, Ordoñez A, Lupo G, Gooptu B, Irving JA, Noto R, Martorana V, Manno M, Timpano V, Guadagno NA, Dalton L, Marciniak SJ, Lomas DA, Miranda E.

FEBS J. 2015 Dec;282(23):4565-79. doi: 10.1111/febs.13517. Epub 2015 Oct 3.

20.

Quantitative proteomic analysis reveals maturation as a mechanism underlying glucocorticoid resistance in B lineage ALL and re-sensitization by JNK inhibition.

Nicholson L, Evans CA, Matheson E, Minto L, Keilty C, Sanichar M, Case M, Schwab C, Williamson D, Rainer J, Harrison CJ, Kofler R, Hall AG, Redfern CP, Whetton AD, Irving JA.

Br J Haematol. 2015 Nov;171(4):595-605. doi: 10.1111/bjh.13647. Epub 2015 Aug 27.

21.

Development and Implementation of an Ambulatory Integrated Care Pathway for Major Depressive Disorder and Alcohol Dependence.

Awan S, Samokhvalov AV, Aleem N, Hendershot CS, Irving JA, Kalvik A, Lefebvre L, Le Foll B, Quilty L, Voore P.

Psychiatr Serv. 2015 Dec 1;66(12):1265-7. doi: 10.1176/appi.ps.201500115. Epub 2015 Aug 17.

PMID:
26278235
22.

Microcystic Stromal Tumor: A Distinctive Ovarian Sex Cord-Stromal Neoplasm Characterized by FOXL2, SF-1, WT-1, Cyclin D1, and β-catenin Nuclear Expression and CTNNB1 Mutations.

Irving JA, Lee CH, Yip S, Oliva E, McCluggage WG, Young RH.

Am J Surg Pathol. 2015 Oct;39(10):1420-6. doi: 10.1097/PAS.0000000000000482.

PMID:
26200099
23.

Deficiency Mutations of Alpha-1 Antitrypsin. Effects on Folding, Function, and Polymerization.

Haq I, Irving JA, Saleh AD, Dron L, Regan-Mochrie GL, Motamedi-Shad N, Hurst JR, Gooptu B, Lomas DA.

Am J Respir Cell Mol Biol. 2016 Jan;54(1):71-80. doi: 10.1165/rcmb.2015-0154OC.

24.

An integrative approach combining ion mobility mass spectrometry, X-ray crystallography, and nuclear magnetic resonance spectroscopy to study the conformational dynamics of α1 -antitrypsin upon ligand binding.

Nyon MP, Prentice T, Day J, Kirkpatrick J, Sivalingam GN, Levy G, Haq I, Irving JA, Lomas DA, Christodoulou J, Gooptu B, Thalassinos K.

Protein Sci. 2015 Aug;24(8):1301-12. doi: 10.1002/pro.2706. Epub 2015 Jul 14.

25.

A single-chain variable fragment intrabody prevents intracellular polymerization of Z α1-antitrypsin while allowing its antiproteinase activity.

Ordóñez A, Pérez J, Tan L, Dickens JA, Motamedi-Shad N, Irving JA, Haq I, Ekeowa U, Marciniak SJ, Miranda E, Lomas DA.

FASEB J. 2015 Jun;29(6):2667-78. doi: 10.1096/fj.14-267351. Epub 2015 Mar 10.

26.

An antibody raised against a pathogenic serpin variant induces mutant-like behaviour in the wild-type protein.

Irving JA, Miranda E, Haq I, Perez J, Kotov VR, Faull SV, Motamedi-Shad N, Lomas DA.

Biochem J. 2015 May 15;468(1):99-108. doi: 10.1042/BJ20141569.

27.

A two-factor model of relapse/recurrence vulnerability in unipolar depression.

Farb NA, Irving JA, Anderson AK, Segal ZV.

J Abnorm Psychol. 2015 Feb;124(1):38-53. doi: 10.1037/abn0000031.

28.

Characterising the association of latency with α(1)-antitrypsin polymerisation using a novel monoclonal antibody.

Tan L, Perez J, Mela M, Miranda E, Burling KA, Rouhani FN, DeMeo DL, Haq I, Irving JA, Ordóñez A, Dickens JA, Brantly M, Marciniak SJ, Alexander GJ, Gooptu B, Lomas DA.

Int J Biochem Cell Biol. 2015 Jan;58:81-91. doi: 10.1016/j.biocel.2014.11.005. Epub 2014 Nov 13.

29.

Cytarabine preferentially induces mutation at specific sequences in the genome which are identifiable in relapsed acute myeloid leukaemia.

Fordham SE, Cole M, Irving JA, Allan JM.

Leukemia. 2015 Feb;29(2):491-4. doi: 10.1038/leu.2014.284. Epub 2014 Sep 24. No abstract available.

30.

Ras/Raf/MEK/ERK Pathway Activation in Childhood Acute Lymphoblastic Leukemia and Its Therapeutic Targeting.

Knight T, Irving JA.

Front Oncol. 2014 Jun 24;4:160. doi: 10.3389/fonc.2014.00160. eCollection 2014. Review.

31.

[Mindfulness-based cognitive therapy : current status and future applications].

Irving JA, Segal ZV.

Sante Ment Que. 2013 Autumn;38(2):65-82. Review. French.

PMID:
24719003
32.

Altered native stability is the dominant basis for susceptibility of α1-antitrypsin mutants to polymerization.

Irving JA, Haq I, Dickens JA, Faull SV, Lomas DA.

Biochem J. 2014 May 15;460(1):103-15. doi: 10.1042/BJ20131650.

33.

Recurrent intestinal mucinous borderline tumors of the ovary: a report of 5 cases causing problems in diagnosis, including distinction from mucinous carcinoma.

Irving JA, Clement PB.

Int J Gynecol Pathol. 2014 Mar;33(2):156-65. doi: 10.1097/PGP.0b013e31828bb4c5.

PMID:
24487471
34.

Appendiceal or cecal endometriosis with intestinal metaplasia: a potential mimic of appendiceal mucinous neoplasms.

Misdraji J, Lauwers GY, Irving JA, Batts KP, Young RH.

Am J Surg Pathol. 2014 May;38(5):698-705. doi: 10.1097/PAS.0000000000000167.

PMID:
24451279
35.

HNF-1β in ovarian carcinomas with serous and clear cell change.

DeLair D, Han G, Irving JA, Leung S, Ewanowich CA, Longacre TA, Gilks CB, Soslow RA.

Int J Gynecol Pathol. 2013 Nov;32(6):541-6. doi: 10.1097/PGP.0b013e318273fd07.

36.

Variation at 10p12.2 and 10p14 influences risk of childhood B-cell acute lymphoblastic leukemia and phenotype.

Migliorini G, Fiege B, Hosking FJ, Ma Y, Kumar R, Sherborne AL, da Silva Filho MI, Vijayakrishnan J, Koehler R, Thomsen H, Irving JA, Allan JM, Lightfoot T, Roman E, Kinsey SE, Sheridan E, Thompson P, Hoffmann P, Nöthen MM, Mühleisen TW, Eisele L, Zimmermann M, Bartram CR, Schrappe M, Greaves M, Stanulla M, Hemminki K, Houlston RS.

Blood. 2013 Nov 7;122(19):3298-307. doi: 10.1182/blood-2013-03-491316. Epub 2013 Aug 30.

37.

Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk.

Chubb D, Weinhold N, Broderick P, Chen B, Johnson DC, Försti A, Vijayakrishnan J, Migliorini G, Dobbins SE, Holroyd A, Hose D, Walker BA, Davies FE, Gregory WA, Jackson GH, Irving JA, Pratt G, Fegan C, Fenton JA, Neben K, Hoffmann P, Nöthen MM, Mühleisen TW, Eisele L, Ross FM, Straka C, Einsele H, Langer C, Dörner E, Allan JM, Jauch A, Morgan GJ, Hemminki K, Houlston RS, Goldschmidt H.

Nat Genet. 2013 Oct;45(10):1221-1225. doi: 10.1038/ng.2733. Epub 2013 Aug 18.

38.

Suppression of Aβ toxicity by puromycin-sensitive aminopeptidase is independent of its proteolytic activity.

Kruppa AJ, Ott S, Chandraratna DS, Irving JA, Page RM, Speretta E, Seto T, Camargo LM, Marciniak SJ, Lomas DA, Crowther DC.

Biochim Biophys Acta. 2013 Dec;1832(12):2115-26. doi: 10.1016/j.bbadis.2013.07.019. Epub 2013 Aug 2.

39.

Reactive centre loop mutants of α-1-antitrypsin reveal position-specific effects on intermediate formation along the polymerization pathway.

Haq I, Irving JA, Faull SV, Dickens JA, Ordóñez A, Belorgey D, Gooptu B, Lomas DA.

Biosci Rep. 2013 Jun 25;33(3). pii: e00046. doi: 10.1042/BSR20130038. Erratum in: Biosci Rep. 2013;33(4):e00046c.

40.

A molecular switch governs the interaction between the human complement protease C1s and its substrate, complement C4.

Perry AJ, Wijeyewickrema LC, Wilmann PG, Gunzburg MJ, D'Andrea L, Irving JA, Pang SS, Duncan RC, Wilce JA, Whisstock JC, Pike RN.

J Biol Chem. 2013 May 31;288(22):15821-9. doi: 10.1074/jbc.M113.464545. Epub 2013 Apr 16.

41.

Papillary proliferation of the endometrium: a clinicopathologic study of 59 cases of simple and complex papillae without cytologic atypia.

Ip PP, Irving JA, McCluggage WG, Clement PB, Young RH.

Am J Surg Pathol. 2013 Feb;37(2):167-77. doi: 10.1097/PAS.0b013e318272d428.

PMID:
23211295
42.

The diagnosis of endometrial carcinomas with clear cells by gynecologic pathologists: an assessment of interobserver variability and associated morphologic features.

Fadare O, Parkash V, Dupont WD, Acs G, Atkins KA, Irving JA, Pirog EC, Quade BJ, Quddus MR, Rabban JT 3rd, Vang R, Hecht JL.

Am J Surg Pathol. 2012 Aug;36(8):1107-18. doi: 10.1097/PAS.0b013e31825dd4b3. Erratum in: Am J Surg Pathol. 2013 Mar;37(3):458.

PMID:
22790851
43.

Common genetic variation contributes significantly to the risk of childhood B-cell precursor acute lymphoblastic leukemia.

Enciso-Mora V, Hosking FJ, Sheridan E, Kinsey SE, Lightfoot T, Roman E, Irving JA, Tomlinson IP, Allan JM, Taylor M, Greaves M, Houlston RS.

Leukemia. 2012 Oct;26(10):2212-5. doi: 10.1038/leu.2012.89. Epub 2012 Mar 29.

PMID:
22456626
44.

The serpinopathies studying serpin polymerization in vivo.

Irving JA, Ekeowa UI, Belorgey D, Haq I, Gooptu B, Miranda E, Pérez J, Roussel BD, Ordóñez A, Dalton LE, Thomas SE, Marciniak SJ, Parfrey H, Chilvers ER, Teckman JH, Alam S, Mahadeva R, Rashid ST, Vallier L, Lomas DA.

Methods Enzymol. 2011;501:421-66. doi: 10.1016/B978-0-12-385950-1.00018-3.

PMID:
22078544
45.

Targeting serpins in high-throughput and structure-based drug design.

Chang YP, Mahadeva R, Patschull AO, Nobeli I, Ekeowa UI, McKay AR, Thalassinos K, Irving JA, Haq I, Nyon MP, Christodoulou J, Ordóñez A, Miranda E, Gooptu B.

Methods Enzymol. 2011;501:139-75. doi: 10.1016/B978-0-12-385950-1.00008-0.

PMID:
22078534
46.

NF-κB mediates radio-sensitization by the PARP-1 inhibitor, AG-014699.

Hunter JE, Willmore E, Irving JA, Hostomsky Z, Veuger SJ, Durkacz BW.

Oncogene. 2012 Jan 12;31(2):251-64. doi: 10.1038/onc.2011.229. Epub 2011 Jun 27.

47.

Unravelling the twists and turns of the serpinopathies.

Roussel BD, Irving JA, Ekeowa UI, Belorgey D, Haq I, Ordóñez A, Kruppa AJ, Duvoix A, Rashid ST, Crowther DC, Marciniak SJ, Lomas DA.

FEBS J. 2011 Oct;278(20):3859-67. doi: 10.1111/j.1742-4658.2011.08201.x. Epub 2011 Jun 20. Review.

48.

Müllerian adenosarcomas with unusual growth patterns: staging issues.

Clarke BA, Mulligan AM, Irving JA, McCluggage WG, Oliva E.

Int J Gynecol Pathol. 2011 Jul;30(4):340-7. doi: 10.1097/PGP.0b013e31820b341e.

PMID:
21623203
49.

DNA mismatch repair status affects cellular response to Ara-C and other anti-leukemic nucleoside analogs.

Fordham SE, Matheson EC, Scott K, Irving JA, Allan JM.

Leukemia. 2011 Jun;25(6):1046-9. doi: 10.1038/leu.2011.38. Epub 2011 Mar 4. No abstract available.

PMID:
21372842
50.

Comparative pre-clinical evaluation of receptor tyrosine kinase inhibitors for the treatment of multiple myeloma.

de Brito LR, Batey MA, Zhao Y, Squires MS, Maitland H, Leung HY, Hall AG, Jackson G, Newell DR, Irving JA.

Leuk Res. 2011 Sep;35(9):1233-40. doi: 10.1016/j.leukres.2011.01.011. Epub 2011 Feb 11.

PMID:
21316102

Supplemental Content

Loading ...
Support Center